Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [Go to this article.]

Figure 6
B16- but not CT26 tumor-derived factors inhibit the immunostimulatory capacity of freshly generated BM-DCs. (A and B) CD11c⁺-enriched DCs from BM-DCs cultures were incubated for 4 days in CM or in the presence of CT26 supernatant (CT26 sup) or B16 supernatant (B16 sup) in addition to CpG or ODN-CTR. (A) Graphs show the MFI of CD86 costimulatory molecules on gated IA-b⁺ CD11c⁺ DCs in different culture conditions. (B) Graded numbers of CD11c⁺-enriched BM-DCs cultured for 4 days in different culture conditions were added to 3 × 10⁵ allogeneic (BALB/c) spleen T cells, and T cell proliferation was measured 5 days later. Results shown are representative of three different experiments. *P < 0.05 between B16 supernatant + CpG group compared with B16 supernatant + ODN group. (C) Mice were inoculated with CT26-CCL20 or CT26-mock–transduced tumor cells, and 10 days later CD11c⁺ tumoral DCs were analyzed by flow cytometry. CD86 MFI is written in parentheses above each quadrant. (D and E) Graphs show the MFI of CD86 costimulatory molecules on gated IA-b⁺ CD11c⁺ DCs cultured under different conditions. (D) CD11c⁺-enriched DCs were incubated in B16 supernatant alone or in a 1:1 or 1:10 mixture with CT26 supernatant (B16/CT26 sup) as described in Methods. (E) CD11c⁺-enriched DCs were incubated in CM or in B16 supernatant alone or in addition to neutralizing Ab to TGF-β or IL-10.